ARTICLE | Clinical News
United Therapeutics' esuberaprost fails Phase III in PAH
April 8, 2019 1:42 PM UTC
United Therapeutics discontinued development of esuberaprost after the compound failed to meet the primary endpoint in the Phase III BEAT trial to treat pulmonary arterial hypertension. Esuberaprost is a single isomer formulation of beraprost, a prostacyclin analog.
BEAT evaluated oral esuberaprost as an add-on to Tyvaso, the company's inhaled treprostinil, in PAH patients with signs of deterioration on Tyvaso or who had a suboptimal response to that therapy. The double-blind trial enrolled about 240 patients and evaluated time to first clinical worsening event vs. placebo as its primary endpoint...
BCIQ Company Profiles